YBX1 and melanoma: In line with a general aberrant activation of the MAPK signalling pathway in malignant melanoma, we could already detect elevated levels of activated RSK and therefore of YB-1 phosphorylation in the vemurafenib sensitive parental melanoma cell lines when compared to melanocytes (Supplementary Figure 3A).